PMV PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
PMV PHARMACEUTICALS, INC. (PMVP) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$79.94 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-06
- PMV PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$79.94M.
- PMV PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$74.91M.
- PMV PHARMACEUTICALS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$68.92M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$79.94M 10-K · filed 2026-03-06 |
| 2024-12-31 | -$74.91M 10-K · filed 2026-03-06 |
| 2023-12-31 | -$68.92M 10-K · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |